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Oncogenes and Radiation Carcinogenesis
by Seymour J. Garte* and Frederic J. Burns*
Current research indicates a role for several oncogenes in radiation-induced carcinogenesis in vivo and
cell transformation in vitro. Certain oncogenes are probably also involved in some cases ofhuman cancer
caused by exposure to nonionizing radiation and may play a mechanistic role in the phenomenon of
radioresistance seen in later stages of tumor progression. The mechanisms of oncogene activation seen
in radiation-induced tumors include point mutations, gene amplification, and changes in gene expression.
Genetic factors associated with targetspecies, strain, andtissuetype playan important role indetermining
the specific nature ofoncogene activation by radiation exposure. Using the rat skin as a model for cancer
induction by ionizing radiation, we found concurrent activation of K-ras and c-myc oncogenes in end-
stage tumors. Amplification ofthe myc gene proved to occur during a late stage oftumor progression and
is not an early initiating event resulting from the direct action ofradiation on target cells. The importance
of tissue specificity, tumor cell heterogeneity, and physical characteristics of the radiation exposure are
discussed.
Ras Gene Activation
Ionizingradiation is awell-established environmental
carcinogen for humans and animals. Over several dec-
ades a large body of data has been generated to char-
acterize the effects of dose, dose rate, linear energy
transfer, age, and other factors on cancer induction in
experimental models and human populations exposed to
high levels of radiation (1). Studies of carcinogenic
mechanisms have shown that ionizing radiation pro-
duces a variety of genetic lesions, including chromo-
somal aberrations, DNA strand breaks, deletions, and
gene rearrangements (2). More recently, point muta-
tions have been reported to be a consequence ofradia-
tion exposure (3).
The hypothesis that cellular oncogenes represent an
important class oftargetgenesfortheactionofchemical
carcinogens has been strongly supported by data from
many laboratories using several model systems (4-9).
Considering the well-known effects of radiation as a
DNA damaging agent, it is logical to ask whether there
is evidence that specific cellular genes might represent
target sequences for the action ofionizing radiation re-
lated to carcinogenesis. Such sequences could include
oncogenes, tumor-suppressor genes, integrated viral
sequences, or other genes. In recent years a number of
laboratories have published results of research on the
interaction between radiation and cellular oncogenes.
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Evidencethatcellularoncogenes (bothknownandyet
to be characterized) are in fact likely to be targets for
the effects ofionizingradiation has been obtained using
approaches similar to those used earlier and more ex-
tensively for chemical carcinogens. For example, the
first demonstration of an activated ras oncogene in ra-
diation-induced tumors was done by transfection of
mouse thymoma DNA into NIH 3T3 cells (10). This
group found that the K-ras gene was specifically acti-
vated in radiation-induced thymomas of (AKR x RF/
J) Fl mice, while N-ras was activated in chemically
induced tumors.
The K-ras oncogene has been specifically implicated
in other model systems of radiation-induced carcino-
genesis. In 50% of rat skin carcinomas (11) and 60% of
rat thyroid tumors (12), activated K-ras genes were
detected. In the latter case, the activation ofK-ras was
also carcinogen-specific, since nitrosomethylurea
(NMU)-induced tumors ofthe same type contained ex-
clusively H-ras (12).
However, K-ras is not the only specific target gene
forionizing radiation. Species and straingenetic factors
are important in determining which (if any) oncogene
will be part of the transformation pathway. This was
shown most notably by Pellicer and co-workers, who
found that in radiation-induced thymomas from RF/J
mice, both K- and N-ras genes were mutated, while in
C57B1/6J mice, these tumors contained mostly N-ras
andnovelnon-ras oncogenes (13,14). Incanineleukemia
induced by exposure to gamma radiation from a cobalt
source, the N-ras oncogene was found to be activated
(15). A murine osteosarcoma cell line derived from a
'Sr-induced tumor contained activated H-ras (16).
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The examples discussed so far have been from animal
model studies using ionizing radiation. In humans, ul-
traviolet radiation is an important environmental car-
cinogen, especially in rare DNA repair-deficiency syn-
dromes such as xeroderma pigmentosum (XP). In two
tumors isolated from a single XP patient, the N-ras
oncogene was found to be mutationally activated (17).
In addition, amplification of the c-myc and H-ras on-
cogenes was detected. The mutational activation ofthe
N-ras gene was a rare event, since tumors from seven
otherpatients revealed nomutations inrasgenes. How-
ever, six of ten tumors tested did exhibit amplified H-
ras (17). Another laboratory has reported that a mel-
anoma cell line established from an XP patient also con-
tained an N-ras oncogene activated by the same codon
61 point mutation seen in the first study (18).
In a survey of human skin squamous cell carcinomas
excised from sun-exposed body sites, it was reported
that four of the eight tumors examined exhibited acti-
vated H-ras, and two contained novel non-ras genes
(19). The specificity for N-ras activation in the two XP
studies is not likely therefore to be a function of car-
cinogen-specific (UV) or tissue-specific (human skin)
phenomena, but may possibly be related to the XP gen-
otype.
Other Oncogenes
As might be predicted from the diverse effects of
radiation on the genome, point mutational activation of
ras genes is only one of several types of oncogene al-
terations seen in radiation-induced transformation. We
have shown that many ofthe large rat skin tumors that
harbor an active K-ras gene also exhibit amplified and
overexpressed c-myc (11). Overexpression and ampli-
fication ofthe c-myc gene was also seen in a number of
mouse tumor types induced by ionizing radiation (20).
Overexpression ofc-myc was also observed in some but
not all mouse osteosarcomas (21) and mouse thymomas
(22,23).
Anumberofstudies havebeenpublished dealingwith
effects of radiation on oncogenes in cultured cells. The
incorporation of 125I into the DNA of Chinese hamster
embryo cells led to selective amplification of K-ras and
H-ras (24). Ultraviolet radiation, along with other
DNA-damaging agents, was found to induce c-fos
expression in Chinese hamster ovary cells (25). The im-
portance ofthe genetic background ofthe target cell is
again illustrated by the fact that in mouse C3H1OT 1/2
cells, UV-induced transformant showed a decreased
level of c-fos expression, while c-myc expression was
elevated (26). Two laboratories have reported the de-
tection ofnovel non-ras oncogenes capable ofproducing
foci in the NIH 3T3 transfection assay in C3H1OT 1/2
cells transformed by X-rays (27,28). In one recent
study, the question ofwhether a ras gene can serve as
a target for activation by radiation was tested directly
(29). A plasmid containing the proto-N-ras oncogene
was exposed to UV light and was then capable oftrans-
forming Rat 2 cells. The transformants all showed ac-
tivating mutations at codons 12 or 61 ofthe transfected
N-ras gene.
Oncogenes and Radioresistance
Anunderstandingoftheroleofoncogenesinradiation
carcinogenesis is still at an early stage despite the in-
creased attention being devoted to this issue in the last
2 years. Like many chemicals, radiation is a carcinogen
that is also an effective therapeutic agent. The killing
of cancer cells by radiation is a well-known and impor-
tant therapeutic modality. Also well known is the phe-
nomenon of resistance to radiation-induced cell killing
that often occurs during progression of malignant tu-
mors. Several laboratories have obtained evidence that
cellular oncogenes are involved in the development of
the radioresistant phenotype. A radiation-resistant hu-
man laryngeal cancer cell line was found to contain an
activated raf oncogene (30). The same group has pre-
sented evidence that rafmay be involved in conferring
radioresistance since cDNAs for antisense rafresulted
in modulation of resistance (31). Another laboratory
found a rafgene to be involved in the transforming and
radioresistance activities of DNA from a human skin
cell line (32,33). However, transfection ofrafand other
oncogenes into NIH 3T3 cells produced no clear alter-
ations in radiation sensitivity (34). Different results
have been reported in a study that showed enhanced
radiation resistance in NIH 3T3 cells transformed by
transfectionwithrasoncogenes (35). Transfectionofras
and myc also conferred an increase in radioresistance
to primary fibroblast cells (36,37).
Thestudiesofoncogenesandradiationresistancecon-
cern a later stage of neoplastic progression than initi-
ation ofthe transformed phenotype. The issue oftiming
ofoncogene activation duringthe manytemporal stages
ofcarcinogenesis is complex and poorly understood. In
many model systems, oncogene activation appears to
be an early, perhaps initiating event (4,38). One report
showing increased sensitivity of C3H1OT 1/2 cells to
transformation by ionizing radiation after transfection
with a c-myc gene (39) also suggests an early role for
c-myc expression in radiation-induced cancer.
Rat Skin Carcinogenesis
Tumors ofthe rat skin have proven to be an excellent
model for studying the biological, physical, and molec-
ular aspects ofradiation carcinogenesis (40,41). Our in-
itial experiments using rat skin tumors induced by ion-
izing radiation seemed to implicate activation of c-myc
as a frequent, possibly early event in the carcinogenic
process(11). However, ourmorerecentdatacontradicts
this idea and instead supports the hypothesis that c-
myc amplification is associated with a late stage ofpro-
gression in radiation-induced rat skin carcinogenesis
(42,43).
There are few experimental models of tumor pro-
gression that are as potentially useful for studies of
molecularmechanisms as tumors ofthe skin. The mouse
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skin model, one of the most extensively studied, in-
cludes clearly defined stages of neoplastic progression
from benign papilloma to malignant carcinoma. Al-
though rat skin tumors do not usually arise from benign
lesions, this model also has many advantages for the
study ofprogression (44). Tumors are visible at an early
stage, the growth of individual tumors can be easily
followed, tumors can be repeatedly biopsied during
growth, and tumors ofvarious histologic types are pro-
duced for comparison and analysis of cell-type-specific
phenomena.
Tumors were inducedby exposure of4-week-old male
rats to doses of8to 16 Gyof0.8 MeV electron radiation.
Southern blot hybridization oftumor DNAs to a c-myc
probe showed gene amplification (5- to 10-fold) and re-
striction-fragment polymorphisms in 10 of the 12 tu-
mors. Analyses of tumor RNA revealed enhanced c-
myc expression in amplification-positive tumors. Six of
the 12 radiation-induced tumor DNAs tested were pos-
itive in the NIH 3T3 focus assay, and Southern blot
analysis of transfectant DNA showed that each tumor
contained an activated K-ras oncogene (11). Concurrent
activation ofboth K-ras and c-myc oncogenes was found
in three poorly differentiated clear cell carcinomas. In
four of the five well-differentiated squamous cell car-
cinomas examined, only myc activation was seen (11).
The frequent activation of the c-myc oncogene by
amplification and rearrangements is consistent with the
known clastogenic effects ofionizingradiation on target
DNA. We therefore set out to test the hypothesis that
radiation exposure leads directly to activation ofc-myc,
whichwouldbethefirststepinradiationcarcinogenesis.
We proceeded therefore to examine the activation ofc-
myc as a function of tumor progression, from first ap-
pearance of very small tumors to the development of
large rapidly growing malignant cancers.
Approximately 60 samples of rat skin tumors from
0.1 to 20 cm3 in size were analyzed by Southern blot
hybridization for c-myc gene copy number. These tu-
mors were mostly epithelial, including squamous cell
carcinomas, clearcellcarcinomas, basalcell carcinomas,
keratosebaceous tumors, and carcinomas in situ. Nine
sarcoma samples were also analyzed. Increased c-myc
gene copy number was associated with increased size
in the epithelial tumors. There was a progressive in-
crease in the fraction of tumors containing amplified c-
myc in larger size categories. For example, 7% ofsqua-
mous cell carcinomas that were less than 1 cm3 in size
exhibited a c-myc copy number of 3 or higher, while
47% of these tumors between 1 and 10 cm contained
amplified c-myc. Asimilartrend was observed forother
epithelial tumors. All six ofthe epithelial tumors in the
size class greater than 10 cm3 showed amplification of
c-myc; however, c-myc amplification was not detected
in any sarcomas regardless ofsize class. The difference
between epithelial tumors and sarcomas was statisti-
cally significant (X2 = 5.9, p < 0.01) and suggests cell-
type-specific differences in molecular mechanisms of
neoplasia in rat skin. The average degree ofc-myc am-
plification also increased in larger tumors from an av-
erage of 3-fold in tumors < 1 cm3 to 6-fold for tumors
between 1 and 10 cm3 and 11-fold for tumors greater
than 10 cm3 in size.
Gene amplification was specific for c-myc among the
six oncogenes examined. Although amplification of K-
ras, H-ras, abl, and fos occurred in from 5 to 29% of
the epithelial tumors, no correlation was seen with tu-
mor size. In contrast, linear regression analysis of c-
myc gene copy number with size revealed a highly sig-
nificant (R = 0.66, n = 50, p < 0.001) correlation be-
tween these parameters. Amplification of N-myc was
never found.
Biopsy Studies
We were able to perform molecular analyses on serial
biopsies of growing skin tumors, allowing us to deter-
mine the c-myc gene copy number as a function oftime
in individual tumors. Biopsies were performed on 11
tumors from two to five times each. In all but two cases
the c-myc gene copy numberincreased inthe laterbiop-
sies compared to earlierones. One ofthe two exceptions
was a sarcoma. The other exception was a squamous
cell carcinomathat showed a complex pattern ofgrowth
and c-myc copy number with time. This tumor grew
larger with time until the third biopsy, at which point
it began to regress. Interestingly, the c-myc copy num-
ber also first increased and then decreased in the tumor
during regression, in parallel with the change in tumor
size. A plot oftumor growth rate at each biopsy versus
the c-myc copy number exhibited a good correlation (R
= 0.95, p < 0.05) between these parameters. The in-
tercept (corresponding to a growth rate of 0) of this
curve was very close to 1.
Myc Amplification and Tumor
Growth
Since tumor regression in rat skin carcinogenesis is
rare, one possible explanationforthese results was that
the biopsy procedure involving surgicalremoval oftwo-
thirds ofthetumormasswasresponsible forthe regres-
sion. Autoradiographic data using [3H]thymidine label-
ing of dividing cells supports this interpretation. His-
tologic sections of biopsies 1 to 3 incubated in [3H]
thymidine show a diffuse pattern oflabelingthroughout
the tumor tissue. A section of biopsy 4 shows only a
small region at the edge ofthe tumor to contain intense
labeling. These data are consistent with the hypothesis
that this tumor was composed of heterogeneous sub-
populations ofcells. Itis possible that arapidly dividing
subpopulation containing amplified c-myc was removed
at biopsy, leaving a slower growing, regressing tumor
cell subpopulation with a normal c-myc copy number.
The growth characteristics of radiation-induced rat
skin tumors are complex and diverse. After the initial
appearance ofatumor, there isusually aperiod ofstatic
growth, during which the tumor does not grow and
remains at a small (0.1-0.2 cm3) size. The average du-
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ration of this flat static growth period was determined
to be 12 ± 1 weeks for the tumors used in these ex-
periments.
We found a significant correlation between c-myc
gene copy number and time after tumor appearance
using the composite of all tumor samples and biopsies
(p < 0.01). The intercept of the regression line (corre-
sponding to c-myc gene copy number at tumor appear-
ance) is very close to 1. The average period required
for c-myc gene amplification was calculated to be 14
weeks, very close to the 12-week period ofthe average
static growth phase.
Conclusions
We conclude from our results that c-myc oncogene
amplification is not a frequent early event in radiation-
induced rat skin carcinogenesis. The data presented
here argue against the idea that amplification or other
alterations ofthe c-myc gene was a direct result ofthe
exposure oftarget tissue to the DNA damaging effects
of ionizing radiation. The evidence instead points to a
roleforc-mycintumorprogression intheratskintumor
model.
Amplification of specific genes in cancer is probably
a random event, which is why a diverse assortment of
amplified genes is often found in end-stage tumors. The
ability of transformed cells to amplify genes based on
selective advantage (such as genes for drug resistance)
can be considered to derive from the increased genetic
instability associated with neoplasia. This idea derives
from Nowell's hypothesis of tumor progression (45),
wherein genetic instability and the associated increase
in the frequency of gene amplification leads to the se-
lective growth ofa particular tumor cell subpopulation.
Our data are consistent with the concept that amplifi-
cation ofc-myc confers a significant selective advantage
onacellularsubpopulation inthese tumors. Preliminary
data using in situ hybridization support the idea ofhet-
erogeneity in c-myc copy numberwithin individual cells
ofthese tumors.
Usingastatisticalapproachforevaluation ofthedata,
we concluded that the average time after tumor ap-
pearance (14 weeks) required for amplification ofc-myc
is very close to the average time required for tumor
growth rate to begin to increase. This is suggestive but
does not prove that there is a causal relationship be-
tweenthe onsetofrapidtumorgrowthandthedominant
emergence ofa tumor cellsubpopulation containing am-
plified c-myc.
We have previously explored the role oftissue spec-
ificityinoncogene activationpatternsinmodelsofchem-
ical carcinogenesis (5,46,47). The dramatic difference
observed in myc amplification between radiation-in-
duced skin carcinomas and sarcomas indicates that in
rat skin, as in several other animal models, tumor in-
duction by a single etiological agent often involves the
participation of different molecular pathways in differ-
ent tissue types (48). We have reported evidence for
tissue-specific activation of K-ras in large, late-stage
tumors (11). The activation ofthis gene as a function of
time or progression is currently under investigation.
Although ourresults showthat myc activation occurs
during a late stage in tumorigenesis, it is still possible
that activation ofthis gene is indirectly related to some
effect of the radiation exposure. Studies to clarify the
relationship between carcinogenic etiology and c-myc
activation in rat and human skin tumors induced by
various agents are in progress.
It is anparent that a clearer understanding of the
molecular mechanisms of radiation carcinogenesis will
also require systematic study of the effects of various
parameters such as LET, dose, and dose rate, etc., on
oncogene activation patterns. Arecent report from Pel-
licer's laboratory showed thatmousethymomasinduced
by neutron irradiation exhibited a different pattern of
oncogene activation than that seen with gamma radia-
tion, including a unique ras-activating point mutation
at codon 146 (49). Our laboratory is currently investi-
gating the activation of ras and myc oncogenes in rat
skin tumors induced by high LET neon ions. Radiation
carcinogenesis in animals, radiation sensitivity syn-
dromes in humans, radiation-induced transformation of
cultured cells, and radioresistance are all areas in which
current knowledge concerning cellular oncogenes is still
somewhat fragmentary. However, a clearer picture is
bound to emerge from the recently increased pace of
research in these important areas of carcinogenesis.
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